docetaxel

Understanding the Reality of the Side Effects from Early Chemotherapy

Ever since the research showing that men who are newly diagnosed with very aggressive prostate cancer have a significant life extension advantage if they move immediately to chemotherapy (with docetaxel) along with hormone therapy (ADT) there has been, what I can only describe as a paradigm shift in the clinical care of men with metastatic hormone-sensitive prostate cancer. However, many men are very afraid to have chemotherapy as there remains concerns about the toxicity (side effects) of the drug. A recent study, however, showed that the adverse events experienced by men who have early chemotherapy tends to be short-lived and [...]

Genetic Biomarker Predicts Peripheral Neuropathy Associated With Docetaxel Chemotherapy For Prostate Cancer

According to researchers at the H. Lee Moffitt Cancer Center & Research Institute, men with a mutation in their VAC14 gene are more susceptible to Docetaxil chemotherapy induced neuropathy and nerve pain. This debilitating side effect results from damage to the peripheral nerves and is felt by the man as weakness, numbness and pain most likely felt in the hands and feet. The Moffitt study was published online in the journal Clinical Cancer Research. The researchers analyzed the DNA of 623 men who had participated in a randomized phase 3 clinical trial that included docetaxel chemotherapy therapy. A total of [...]

A new Trend – Chemotherapy for Metastatic Castrate-Sensitive Prostate Cancer

Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, CHAARTED and STAMPEDE. All three of these studies demonstrated a benefit in progression-free survival with the use of ADT along with docetaxel chemotherapy. However, only two of the studies demonstrated a clinically meaningful overall survival benefit (CHAARTED and STAMPEDE), whereas the GETUG15 study did not [...]

Men With Castrate Resistant Prostate Cancer Can Experience A PSA Flare When Starting Docetaxel Chemotherapy

The PSA flare phenomenon when first starting chemotherapy with docetaxel has been noted by many clinicians. To evaluate this flare in men with castrate resistant prostate cancer treated with docetaxel, researchers retrospectively evaluated the charts of 56 men who received docetaxel-based chemotherapy in three different centers from August 1999 to August 2007. They found that there was an immediate PSA decline equal to or more than 50% in 23 (41%) of the men, PSA stabilization or PSA decline less than 50% in 16 (29%) men and PSA progression in nine men (16%). They also found that there was also a [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー